Fact checked byStephanie C. Viguers

Read more

August 11, 2023
1 min read
Save

Top in allergy/asthma: Backlash over FDA’s sesame decision; direct oral penicillin test

Fact checked byStephanie C. Viguers
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Two nonprofits said they are disappointed in the FDA’s decision to reject a request to prevent food companies from adding sesame to products, even though it is an allergen, in efforts to sidestep the agency’s new cross-contamination rules.

FDA Commissioner Robert M. Califf, MD, said the agency intends to “meet the needs of consumers with food allergies, while also taking into account the practical limitations industry may be facing in implementing effective cross-contact controls and allergen labeling.” It was the top story in allergy/asthma last week.

FDA HQ in Washington
Two nonprofits said they are disappointed in the FDA’s decision to reject a request to prevent food companies from adding sesame to products, even though it is an allergen, in efforts to sidestep the agency’s new cross-contamination rules. Image source: Adobe Stock

Another top story was about a study that showed a one-step oral penicillin allergy test, rather than a two-stage skin testing on top of an oral test, was a safe and effective method for testing those with low-risk penicillin allergies.

Read these and more top stories in allergy/asthma below:

Advocacy groups disappointed in FDA sesame allergen decision

The Center for Science in the Public Interest and Food Allergy Research and Education both have expressed disappointment in the FDA’s decision to allow food manufacturers to intentionally add sesame to products to meet regulations. Read more.

Direct oral challenges rival standard of care in assessing low-risk penicillin allergy

Direct oral challenges in adults at low risk for penicillin allergy were safe and not inferior to the standard-of-care oral challenge following two-stage skin testing, according to a study published in JAMA Internal Medicine. Read more.

FDA fast tracks first-line treatment for hereditary angioedema attacks

The FDA has granted fast-track status to STAR-0215, a potential first-line treatment to prevent attacks of hereditary angioedema, Astria Therapeutics Inc. announced in a company press release. Read more.

Five trends will influence care for allergic asthma

Five trends will shape treatment for allergic airway diseases in the years ahead, according to a keynote speaker. Read more.

EHR data reveal patterns in pediatric allergy development

Patterns of pediatric allergy demonstrated a population-level progression of diseases in an atopic march from eczema to food allergies, asthma and environmental allergies, according to a study published in Pediatrics. Read more.